Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 6;10:2484. doi: 10.1038/s41467-019-10127-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — PRL3-zumab recruits immune cells to tumor sites in an FcR-dependent manner. a–c Orthotopic MHCC-LM3 liver tumor tissue cryo-sections from various groups of mice: I) untreated (filled black squares), II) PRL3-zumab treatment (filled red triangles), III) FcR blocker treatment (filled black triangles), and IV) PRL3-zumab plus Fc blocker combination treatment (filled black diamonds) were analyzed by immunofluorescence with antibodies against B220/CD45R (B cells; a), CD335 (NK cells; b), or F4/80 (macrophages; c) and scored for relative tumor infiltration. The mean relative infiltration was calculated using one-way analysis of variance (ANOVA) (mean ± s.e.m., n = 4 independent samples). Lower panels, representative immunofluorescence results for each antibody set. Scale bar, 200 µm. d Proposed mechanism of action of PRL3-zumab. Externalized PRL3 antigens are recognized by PRL3-zumab, which then recruits NK cells, B cells, and Ly-6C⁺F4/80⁺ macrophages for tumor killing and leakage of additional PRL3 antigens (“kill-and-leak” cycle) triggering an anti-tumor ADCC/ADCP cascade. Source data are provided as a Source Data file